Catalyst Pharma Files 8-K on Other Events and Exhibits
Ticker: CPRX · Form: 8-K · Filed: Feb 21, 2024 · CIK: 1369568
| Field | Detail |
|---|---|
| Company | Catalyst Pharmaceuticals, Inc. (CPRX) |
| Form Type | 8-K |
| Filed Date | Feb 21, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K filing, corporate-disclosure, other-events
TL;DR
**Catalyst Pharma just dropped an 8-K for 'Other Events' and 'Financials', so keep an eye out for what's next!**
AI Summary
CATALYST PHARMACEUTICALS, INC. filed an 8-K on February 21, 2024, reporting 'Other Events' and 'Financial Statements and Exhibits'. The filing indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company, based in Coral Gables, Florida, with IRS Employer Identification No. 76-0837053, has a Commission File Number 001-33057.
Why It Matters
This filing signals that Catalyst Pharmaceuticals has an event or information deemed significant enough to warrant immediate disclosure to investors, potentially impacting market perception or future operations.
Risk Assessment
Risk Level: low — The 8-K filing itself is a standard disclosure and does not inherently indicate high risk without further details on the 'Other Events'.
Key Players & Entities
- CATALYST PHARMACEUTICALS, INC. (company) — Registrant
- February 21, 2024 (date) — Date of Report
- 001-33057 (other) — Commission File Number
- 76-0837053 (other) — I.R.S. Employer Identification No.
- Coral Gables, Florida (other) — Principal Executive Office Location
FAQ
What is the purpose of this 8-K filing by Catalyst Pharmaceuticals, Inc.?
The 8-K filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically reporting 'Other Events' and 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The Date of Report (Date of Earliest Event Reported) is February 21, 2024.
What is the Commission File Number for Catalyst Pharmaceuticals, Inc.?
The Commission File Number for Catalyst Pharmaceuticals, Inc. is 001-33057.
Where is Catalyst Pharmaceuticals, Inc.'s principal executive office located?
The principal executive office of Catalyst Pharmaceuticals, Inc. is located at 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134.
What is the IRS Employer Identification Number for Catalyst Pharmaceuticals, Inc.?
The I.R.S. Employer Identification No. for Catalyst Pharmaceuticals, Inc. is 76-0837053.
Filing Stats: 458 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-02-21 16:34:10
Key Financial Figures
- $0.001 — Ticker Symbol Common Stock, par value $0.001 per share NASDAQ Capital Market CPR
Filing Documents
- d706892d8k.htm (8-K) — 25KB
- d706892dex991.htm (EX-99.1) — 16KB
- 0001193125-24-041520.txt ( ) — 167KB
- cprx-20240221.xsd (EX-101.SCH) — 3KB
- cprx-20240221_lab.xml (EX-101.LAB) — 18KB
- cprx-20240221_pre.xml (EX-101.PRE) — 11KB
- d706892d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press release issued by the Company on February 21, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Catalyst Pharmaceuticals, Inc. By: /s/ Michael W. Kalb Michael W. Kalb Executive Vice President and Chief Financial Officer Dated: February 21, 2024 3